## CITATION REPORT List of articles citing



DOI: 10.1111/j.1872-034x.2007.00168.x Hepatology Research, 2007, 37 Suppl 2, S88-94.

Source: https://exaly.com/paper-pdf/42959930/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
273	Review of 4th Single Topic Conference on HCC. Hepatocellular carcinoma: International consensus and controversies. <i>Hepatology Research</i> , <b>2007</b> , 37 Suppl 2, S83-7	5.1	7
272	Resection or ablation of small hepatocellular carcinoma: what is the better treatment?. <b>2008</b> , 49, 502-4		14
271	Hepatocellular carcinoma. <b>2008</b> , 54, 432-44		9
270	[Epidemiology, risk factors and molecular pathogenesis of primary liver cancer]. 2008, 149, 541-8		20
269	Heat shock protein A1B 1267 polymorphism is highly associated with risk and prognosis of hepatocellular carcinoma: a case-control study. <b>2008</b> , 87, 87-98		19
268	Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. <b>2008</b> , 75 Suppl 1, 1-12		95
267	Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolizationsingle-center experience. <b>2008</b> , 249, 346-54		52
266	Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. <i>World Journal of Gastroenterology</i> , <b>2008</b> , 14, 4300-8	5.6	494
265	Sorafenib, a systemic therapy for hepatocellular carcinoma. <i>Annals of Hepatology</i> , <b>2008</b> , 7, 46-51	3.1	25
264	Surgical resection for hepatocellular carcinoma. 2008,		4
263	Article Commentary: Clinical Medicine: Endocrinology and Diabetes: Insulin Resistance Link between Inflammation and Hepatocarcinogenesis?. <b>2009</b> , 2, CMED.S3497		
262	Hepatocellular carcinoma prevalence and mortality in a male state prison population. <b>2009</b> , 124, 120-6		13
261	Role of hepatitis B virus X repression of C/EBPbeta activity in the down-regulation of glutathione S-transferase A2 gene: implications in other phase II detoxifying enzyme expression. <b>2009</b> , 39, 182-92		8
260	Hepatitis C and hepatocellular carcinoma: New developments in natural history and treatment. <b>2009</b> , 8, 59-65		
259	Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. <b>2009</b> , 24, 955-61		55
258	Prevention of hepatocellular carcinoma complicating chronic hepatitis C. <b>2009</b> , 24, 531-6		32
257	Expression and prognostic significance of the alpha B-crystallin gene in human hepatocellular carcinoma. <b>2009</b> , 40, 300-5		43

## (2010-2009)

	Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. <b>2009</b> , 3, 353-67		221
255	Imaging approach for evaluation of focal liver lesions. <b>2009</b> , 7, 624-34		9
254	Safety of liver resections in obese and overweight patients. <b>2010</b> , 34, 2960-8		54
253	Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: expertsRopinion. <b>2010</b> , 30, 1427-38		32
252	The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. <b>2010</b> , 25, 439-52		82
251	Screening for hepatocellular carcinoma: good enough but best yet to come. <b>2010</b> , 25, 845-6		1
250	Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. <i>Annals of Hepatology</i> , <b>2010</b> , 9, 63-69	3.1	35
249	Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre. <b>2010</b> , 17, 6-12		6
248	An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithm. <b>2010</b> , 24, 643-50		28
247	Importance of hepatitis C virus-associated insulin resistance: therapeutic strategies for insulin sensitization. World Journal of Gastroenterology, 2010, 16, 1943-52	5.6	46
	2		
246	Population-based risk factors and resource utilization for HCC: US perspective. <b>2010</b> , 26, 2183-91		217
246 245			217
,	Population-based risk factors and resource utilization for HCC: US perspective. <b>2010</b> , 26, 2183-91		
245	Population-based risk factors and resource utilization for HCC: US perspective. <b>2010</b> , 26, 2183-91  Hepatitis B and C viruses and hepatocellular carcinoma. <b>2010</b> , 2, 1504-9  Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for		31
245	Population-based risk factors and resource utilization for HCC: US perspective. <b>2010</b> , 26, 2183-91  Hepatitis B and C viruses and hepatocellular carcinoma. <b>2010</b> , 2, 1504-9  Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer. <b>2010</b> , 37,  Management of hepatocellular carcinoma: from prevention to molecular targeted therapy. <b>2010</b> ,		31 9
<ul><li>245</li><li>244</li><li>243</li></ul>	Population-based risk factors and resource utilization for HCC: US perspective. 2010, 26, 2183-91  Hepatitis B and C viruses and hepatocellular carcinoma. 2010, 2, 1504-9  Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer. 2010, 37,  Management of hepatocellular carcinoma: from prevention to molecular targeted therapy. 2010, 78 Suppl 1, 1-6  Disparities in hepatocellular carcinoma survival among Californians of Asian ancestry, 1988 to 2007.		31 9 17
245 244 243	Population-based risk factors and resource utilization for HCC: US perspective. 2010, 26, 2183-91  Hepatitis B and C viruses and hepatocellular carcinoma. 2010, 2, 1504-9  Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer. 2010, 37,  Management of hepatocellular carcinoma: from prevention to molecular targeted therapy. 2010, 78 Suppl 1, 1-6  Disparities in hepatocellular carcinoma survival among Californians of Asian ancestry, 1988 to 2007. 2010, 19, 2747-57		31 9 17 33

238	Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. <b>2010</b> , 138, 513-21, 521.e1-6		720
237	Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population. <b>2010</b> , 9, 1096-103		66
236	Liver transplantation is an alternative treatment of hepatocellular carcinoma beyond the Milan criteria. <b>2010</b> , 200, 252-7		17
235	Global patterns of cancer incidence and mortality rates and trends. <b>2010</b> , 19, 1893-907		1911
234	An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels. <b>2011</b> , 20, 1039-45		8
233	Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management. <b>2011</b> , 258, 673-93		57
232	[Evaluation of noninvasive diagnostic criteria for hepatocellular carcinoma on pretransplant MRI (2010): correlation between MR imaging features and histological features on liver specimen]. <b>2011</b> , 92, 688-700		15
231	Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications. <b>2011</b> , 9, 525-33		26
230	Insulin resistance and metabolic hepatocarcinogenesis with parent-of-origin effects in AB mice. <b>2011</b> , 179, 2855-65		20
229	Data mining reveals complex interactions of risk factors and clinical feature profiling associated with the staging of non-hepatitis B virus/non-hepatitis C virus-related hepatocellular carcinoma. <i>Hepatology Research</i> , <b>2011</b> , 41, 564-71	5.1	11
228	Inconsistency in the Management of Patients with Hepatocellular Carcinoma: The Need for a Strict Protocol. <b>2011</b> , 77, 207-214		3
227	Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. <b>2011</b> , 18, 228-40		44
226	Trichloroethylene and cancer: systematic and quantitative review of epidemiologic evidence for identifying hazards. <b>2011</b> , 8, 4238-72		66
225	Genetic variations in plasma circulating DNA of HBV-related hepatocellular carcinoma patients predict recurrence after liver transplantation. <b>2011</b> , 6, e26003		11
224	Octreotide induces caspase activation and apoptosis in human hepatoma HepG2 cells. <i>World Journal of Gastroenterology</i> , <b>2011</b> , 17, 313-21	5.6	19
223	Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. <b>2011</b> , 26, 1757-64		41
222	Use of HOMA-IR in hepatitis C. <i>Journal of Viral Hepatitis</i> , <b>2011</b> , 18, 675-84	3.4	31
221	Global cancer statistics. <b>2011</b> , 61, 69-90		26395

220	MicroRNA122 is a key regulator of Fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. <b>2011</b> , 2, 338	83
219	Hepatitis B and hepatocellular carcinoma screening among Asian Americans: survey of safety net healthcare providers. <b>2011</b> , 56, 1516-23	46
218	Long-term experience with liver transplantation for hepatocellular carcinoma. 2011, 46, 249-56	19
217	Guest editorß introduction: hepatocellular nodules in liver cirrhosis: imaging update 2011. <b>2011</b> , 36, 230-1	
216	Hospitalization for complications of cirrhosis: does volume matter?. <b>2011</b> , 15, 330-5	5
215	Prognosis of patients with hepatocellular carcinoma after hepatic resection: are elderly patients suitable for surgery?. <b>2011</b> , 104, 284-91	60
214	Underutilization of therapy for hepatocellular carcinoma in the medicare population. <b>2011</b> , 117, 1019-26	57
213	A comparative evaluation of Golgi protein-73, fucosylated hemopexin, Fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma. <b>2011</b> , 49, 711-8	46
212	Upregulation of Rac GTPase-activating protein 1 is significantly associated with the early recurrence of human hepatocellular carcinoma. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 6040-51	109
211	International trends in liver cancer incidence rates. <b>2011</b> , 20, 2362-8	189
210	Combined inhibitors of angiogenesis and histone deacetylase: efficacy in rat hepatoma. World Journal of Gastroenterology, <b>2011</b> , 17, 3623-9	3
209	Risk factors for early-onset and late-onset hepatocellular carcinoma in Asian immigrants with hepatitis B in the United States. <b>2011</b> , 106, 1994-2000	23
208	Resistance to paclitaxel in hepatoma cells is related to static JNK activation and prohibition into entry of mitosis. <b>2012</b> , 302, G1016-24	15
207	Association of Hepatitis C Virus With Insulin Resistance: Evidences From Animal Studies and Clinical Studies. <i>Hepatitis Monthly</i> , <b>2012</b> , 12, 11-15	2
206	Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. <b>2012</b> , 61, 427-38	234
205	Adding 11C-acetate to 18F-FDG at PET Examination Has an Incremental Value in the Diagnosis of Hepatocellular Carcinoma. <b>2012</b> , 21, 6-12	12
204	New paradigm for management of hepatocellular carcinoma by imaging. <i>Liver Cancer</i> , <b>2012</b> , 1, 94-109 9.1	34
203	Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma:  Role of mTOR Inhibition. <i>Liver Cancer</i> , <b>2012</b> , 1, 247-56	60

202	Testing for HCV: the first step in preventing disease transmission and improving health outcomes for HCV-infected individuals. <b>2012</b> , 17, 1397-401		12
201	Safety of hepatic resections in obese veterans. <b>2012</b> , 147, 331-7		21
200	Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. <b>2012</b> , 157, 817-22		226
199	Anticarcinogenic impact of interferon therapy on the progression of hepatocellular carcinoma in patients with chronic viral infection. <i>Hepatology Research</i> , <b>2012</b> , 42, 22-32	5.1	7
198	Hepatocellular carcinoma: insight from animal models. <b>2011</b> , 9, 32-43		91
197	Liver resection for hepatocellular carcinoma B cm: results of an Italian multicenter study on 588 patients. <b>2012</b> , 215, 244-54		33
196	Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. <b>2012</b> , 10, 1342-1359.e2		486
195	Comparison of outcomes of transplantation and resection in patients with early hepatocellular carcinoma: a meta-analysis. <b>2012</b> , 14, 635-45		66
194	Increased activity of serum mitochondrial isoenzyme of creatine kinase in hepatocellular carcinoma patients predominantly with recurrence. <b>2012</b> , 57, 330-6		13
193	A miRNA machinery component DDX20 controls NF- <b>B</b> via microRNA-140 function. <b>2012</b> , 420, 564-9		22
192	Recent advances in metabolomics in oncology. <b>2012</b> , 4, 431-51		48
191	Fibrosis-dependent mechanisms of hepatocarcinogenesis. <b>2012</b> , 56, 769-75		278
190	Prospective study of ultraviolet radiation exposure and risk of cancer in the United States. <b>2012</b> , 131, E1015-23		74
189	mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. <b>2012</b> , 4, 139ra84		76
188	Hepatitis C virus prevention, care, and treatment: from policy to practice. <b>2012</b> , 55 Suppl 1, S58-63		31
187	Sorafenib for treatment of hepatocellular carcinoma: a systematic review. <b>2012</b> , 57, 1122-9		95
186	Identification of osteopontin as a novel marker for early hepatocellular carcinoma. <b>2012</b> , 55, 483-90		223
185	Risk factors for hepatocellular carcinoma in patients with chronic liver disease: a case-control study. <i>Cancer Causes and Control</i> , <b>2012</b> , 23, 455-62	2.8	28

## (2013-2012)

184	An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. <b>2012</b> , 30, 387-94		52	
183	Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma: clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection. <b>2013</b> , 119, 126-35		40	
182	Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy. <b>2013</b> , 201, 80-96		62	
181	Operative microwave ablation for hepatocellular carcinoma: complications, recurrence, and long-term outcomes. <b>2013</b> , 17, 719-29		59	
180	Patterns of consultation and treatment of patients with hepatocellular carcinoma presenting to a large academic medical center in the US. <b>2013</b> , 17, 1600-8		12	
179	Neuroimmunomodulation in human autoimmune liver disease. <b>2013</b> , 354, 543-50		4	
178	Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 784-93	6.1	17	
177	After the cure: management of HCV after achievement of SVR. <b>2013</b> , 10, 428-35		10	
176	The impact of chronic hepatitis C on resource utilisation and in-patient mortality for Medicare beneficiaries between 2005 and 2010. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 1065-75	6.1	28	
175	Prediction of macroscopic findings of hepatocellular carcinoma on hepatobiliary phase of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging: Correlation with pathology. <i>Hepatology Research</i> , <b>2013</b> , 43, 488-94	5.1	11	
174	Correcting the misnomers of epithelial-mesenchymal relations. <b>2013</b> , 182, 36-9		2	
173	Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma. <b>2013</b> , 82, 1471-80		23	
172	Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma. <b>2013</b> , 30, 446		27	
171	Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies. <b>2013</b> , 57, 1068-77		19	
170	The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. <b>2013</b> , 58, 54-64		65	
169	Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers. <b>2013</b> , 22, 341-56		24	
168	Surgical resection versus liver transplant for patients with hepatocellular carcinoma. 2013, CD006935		15	
167	Berberine induces apoptosis via the mitochondrial pathway in liver cancer cells. <b>2013</b> , 30, 1107-12		45	

166	Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker. <b>2013</b> , 267, 776-86		133
165	Histopathology of hepatocellular carcinoma. <b>2013</b> , 190, 21-32		38
164	Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. <b>2013</b> , 34, 1800-5		63
163	Viral hepatitis markers in liver tissue in relation to serostatus in hepatocellular carcinoma. <b>2013</b> , 22, 20 <sup>7</sup>	16-23	4
162	Peroxisome proliferator-activated receptor-lactivation inhibits hepatocellular carcinoma cell invasion by upregulating plasminogen activator inhibitor-1. <b>2013</b> , 104, 672-80		21
161	Cancer en Chile y el mundo: Una mirada epidemiologica, presente y futuro. <b>2013</b> , 24, 531-552		3
160	Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. <b>2013</b> , 158, 329-37		593
159	Liver transplantation for hepatocellular carcinoma. <i>Liver Cancer</i> , <b>2013</b> , 2, 338-44	9.1	40
158	Berberine induces selective apoptosis through the AMPK-mediated mitochondrial/caspase pathway in hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , <b>2013</b> , 8, 505-10	2.9	48
157	Potential consequences of healthcare recommendations: a focus on the U.S. Preventive Services Task Force. <b>2013</b> , 58, 422-7		2
156	Survival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma. <b>2013</b> , 257, 686-92		51
155	Drug-eluting bead transarterial chemoembolisation for unresectable hepatocellular carcinoma. <b>2013</b> ,		
154	Cellular basis of hepatic fibrosis and its role in inflammation and cancer. <b>2013</b> , 5, 217-30		82
153	Integrative genomic analysis identifies that SERPINA6-rs1998056 regulated by FOXA/ER\(\text{B}\)s associated with female hepatocellular carcinoma. <b>2014</b> , 9, e107246		8
152	Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma?. <b>2014</b> , 9, e111935		14
151	Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: a policy statement and implementation guideline. <b>2014</b> , 28, 529-34		5
150	The gap in digestive organ cancers in Inner Mongolia, 2009-2012. <b>2014</b> , 7, 209-14		
149	Epidemiology of hepatitis C: related hepatocellular carcinoma in Cameroon. <b>2014</b> , 19, 379		2

148	Micro-ribonucleic acids: potential noninvasive biomarkers for hepatocellular carcinoma. <b>2014</b> , 1, 21-33	1
147	Predictors of mortality in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. <b>2014</b> , 59, 2821-5	17
146	Hepatocellular carcinoma and cholangiocarcinoma: an update. <b>2014</b> , 8, 63-82	15
145	Factors related to hepatitis B screening among Africans in New York City. <b>2014</b> , 38, 745-54	31
144	Laparoscopic-assisted ablation of hepatic tumors: a review. <b>2014</b> , 31, 125-8	1
143	Hepatitis C screening beyond CDC guidelines in an Egyptian immigrant community. <b>2014</b> , 34, 253-8	11
142	Modeling human liver cancer heterogeneity: virally induced transgenic models and mouse genetic models of chronic liver inflammation. <b>2014</b> , 67, Unit 14.31.1-17	4
141	Mechanism of inhibition for BMS-791325, a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase. <b>2014</b> , 289, 33456-68	20
140	Increased serum mitochondrial creatine kinase activity as a risk for hepatocarcinogenesis in chronic hepatitis C patients. <b>2014</b> , 135, 871-9	5
139	Survival analysis of patients with stage I and II hepatocellular carcinoma after a liver transplantation or liver resection. <b>2014</b> , 16, 1102-9	25
138	Diabetes and racial/ethnic differences in hepatocellular carcinoma risk: the multiethnic cohort. <b>2014</b> , 106,	34
137	The glypican 3 hepatocellular carcinoma marker regulates human hepatic stellate cells via Hedgehog signaling. <b>2014</b> , 187, 377-85	27
136	Treatment options and surveillance strategies after therapy for hepatocellular carcinoma. <b>2014</b> , 21, 758-66	33
135	MELD: Which Patients Fall Through the Cracks?. <b>2014</b> , 13, 60-73	1
134	Epidemiology and risk factors of biliary tract and primary liver tumors. <i>Surgical Oncology Clinics of North America</i> , <b>2014</b> , 23, 171-88	34
133	Hepatitis C virus screening in patients with cancer receiving chemotherapy. <b>2014</b> , 10, e167-74	14
132	Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment. <b>2014</b> , 63, 1668-76	83
131	Significance of plasma osteopontin in diagnosis of hepatitis C virus-related hepatocellular carcinoma. <b>2014</b> , 15, 103-7	12

130	Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans. <b>2014</b> , 60, 1291-301	49
129	Effect of pre- and post-treatment Hetoprotein levels and tumor size on survival of patients with hepatocellular carcinoma treated by resection, transarterial chemoembolization or radiofrequency ablation: a retrospective study. <b>2014</b> , 14, 40	44
128	Utility of contrast-enhanced ultrasound with perflubutane for diagnosing the macroscopic type of small nodular hepatocellular carcinomas. <b>2014</b> , 24, 2157-66	11
127	Epidemiology of metastatic hepatocellular carcinoma, a nationwide perspective. <b>2014</b> , 59, 2813-20	24
126	Methylation of multiple genes in hepatitis C virus associated hepatocellular carcinoma. <b>2014</b> , 5, 27-40	31
125	Local geographic variation in chronic liver disease and hepatocellular carcinoma: contributions of socioeconomic deprivation, alcohol retail outlets, and lifestyle. <b>2014</b> , 24, 104-10	30
124	Assessment of hepatitis C risk factors and infection prevalence in a jail population. <b>2014</b> , 104, 1722-7	19
123	Imaging Techniques for the Diagnosis of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. <b>2015</b> , 162, 697-711	112
122	Hepatocellular carcinoma in Asia: Prevention strategy and planning. <i>World Journal of Hepatology</i> , <b>2015</b> , 7, 1708-17	67
121	Drug-eluting bead transarterial chemoembolisation for unresectable hepatocellular carcinoma. <b>2015</b> ,	
120	Evaluation of alpha-fetoprotein as a screening marker for hepatocellular carcinoma in hepatitis prevalent areas. <i>Annals of Hepatology</i> , <b>2015</b> , 14, 882-8	15
119	Risk factors for hepatocellular carcinoma in Caucasian patients with non-viral cirrhosis: the importance of prior obesity. <b>2015</b> , 35, 1872-6	15
118	Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatocellular Carcinoma: How Common?. 2015, 14, 87-98	1
117	Dectin-1 Regulates Hepatic Fibrosis and Hepatocarcinogenesis by Suppressing TLR4 Signaling Pathways. <b>2015</b> , 13, 1909-1921	48
116	Comparison of gadoxetic acid and gadopentetate dimeglumine-enhanced MRI for HCC detection: prospective crossover study at 3 T. <b>2015</b> , 4, 2047981614561285	13
115	Restoration of epigenetically silenced SULF1 expression by 5-aza-2-deoxycytidine sensitizes hepatocellular carcinoma cells to chemotherapy-induced apoptosis. <b>2015</b> , 3, 1-18	7
114	Safe hepatectomy selection criteria for hepatocellular carcinoma patients: a validation of 336 consecutive hepatectomies. The BILCHE score. <b>2015</b> , 39, 237-43	34
113	Hepatitis C virus infection, antiviral therapy, and risk of hepatocellular carcinoma. <b>2015</b> , 42, 329-38	17

112	Diagnosing Borderline Hepatic Nodules in Hepatocarcinogenesis: Imaging Performance. <b>2015</b> , 205, 10-21	30
111	Resource utilization and survival among Medicare patients with advanced liver disease. <b>2015</b> , 60, 320-32	9
110	Surgical Outcomes of Hepatic Resection for Hepatitis B Virus Surface Antigen-Negative and Hepatitis C Virus Antibody-Negative Hepatocellular Carcinoma. <b>2015</b> , 22, 2279-85	5
109	mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice. <b>2015</b> , 149, 741-52.e14	46
108	Comparison between accuracy of different scoring systems in prediction of liver cirrhosis-related complications. <b>2015</b> , 5, 6-14	
107	Modern multimodality diagnosis of portal vein infiltration in hepatocellular carcinoma and expected changes during current therapies. <b>2015</b> , 56, 1283-92	6
106	Pesticide exposure and hepatocellular carcinoma risk: A case-control study using a geographic information system (GIS) to link SEER-Medicare and California pesticide data. <b>2015</b> , 143, 68-82	39
105	Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis. <b>2015</b> , 35, 751-9	19
104	Diagnosis of Hepatobiliary Malignancies. <b>2015</b> , 471-502	
103	Diagnostic accuracy for macroscopic classification of nodular hepatocellular carcinoma: comparison of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and angiography-assisted computed tomography. <b>2015</b> , 50, 85-94	16
102	Hepatitis C virus-associated cancer. <b>2015</b> , 10, 345-70	66
101	Coffee consumption and risk of hepatocellular carcinoma: a meta-analysis of eleven epidemiological studies. <b>2016</b> , 9, 4369-75	15
100	INFLUENCE OF HEPATOCELLULAR CARCINOMA ETIOLOGY IN THE SURVIVAL AFTER RESECTION. <b>2016</b> , 29, 105-8	9
99	Metabolic derivatives of alcohol and the molecular culprits of fibro-hepatocarcinogenesis: Allies or enemies?. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 50-71	10
98	Galectin-1-Induced Autophagy Facilitates Cisplatin Resistance of Hepatocellular Carcinoma. <b>2016</b> , 11, e0148408	45
97	Results of Hepatitis C Birth-Cohort Testing and Linkage to Care in Selected U.S. Sites, 2012-2014. <b>2016</b> , 131 Suppl 2, 12-9	28
96	UHPLC-MS-based metabolomics analysis on mice bearing neoplasm (H22) for hispidulin. <b>2016</b> , 125, 310-8	7
95	Chronic Hepatitis B Is Associated with Higher Inpatient Resource Utilization and Mortality Versus Chronic Hepatitis C. <b>2016</b> , 61, 2505-15	9

94	Hepatocellular Carcinoma and Viral Hepatitis in New York City. <b>2016</b> , 63, 1577-1583	11
93	Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. <b>2016</b> , 122, 1312-37	629
92	Higher Glucose and Insulin Levels Are Associated with Risk of Liver Cancer and Chronic Liver Disease Mortality among Men without a History of Diabetes. <i>Cancer Prevention Research</i> , <b>2016</b> , 9, 866-874 <sup>2</sup>	14
91	Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker. <b>2016</b> , 5, 297-304	6
90	Environmental Carcinogens and Risk for Human Liver Cancer. <b>2016</b> , 25-41	
89	Clinicopathological Features and Metastatic Pattern of Hepatocellular Carcinoma: An Autopsy Study of 398 Patients. <b>2016</b> , 83, 301-7	14
88	miR-10b exerts oncogenic activity in human hepatocellular carcinoma cells by targeting expression of CUB and sushi multiple domains 1 (CSMD1). <b>2016</b> , 16, 806	49
87	Could ADC values be a promising diagnostic criterion for differentiating malignant and benign hepatic lesions in Asian populations: A meta-analysis. <b>2016</b> , 95, e5470	4
86	Clinical characteristics and potential aetiologies of non-B non-C hepatocellular carcinoma in hepatitis B virus endemic area. <b>2016</b> , 36, 1351-61	15
85	The Liver in Systemic Diseases. <b>2016</b> ,	1
8 <sub>5</sub>	The Liver in Systemic Diseases. <b>2016</b> ,  The rationale for targeting TGF-In chronic liver diseases. <b>2016</b> , 46, 349-61	1
84	The rationale for targeting TGF-In chronic liver diseases. <b>2016</b> , 46, 349-61  Limitations of the barcelona clinic liver cancer staging system with a focus on transarterial	46
84	The rationale for targeting TGF-lin chronic liver diseases. <b>2016</b> , 46, 349-61  Limitations of the barcelona clinic liver cancer staging system with a focus on transarterial chemoembolization as a key modality for treatment of hepatocellular carcinoma. <b>2016</b> , 7, 32-35  Erratum to: Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis.	46 8
84 83 82	The rationale for targeting TGF-lin chronic liver diseases. <b>2016</b> , 46, 349-61  Limitations of the barcelona clinic liver cancer staging system with a focus on transarterial chemoembolization as a key modality for treatment of hepatocellular carcinoma. <b>2016</b> , 7, 32-35  Erratum to: Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis. <b>2016</b> , 36, 93-6  Hepatic Arterial Infusion of Low-Density Lipoprotein Docosahexaenoic Acid Nanoparticles Selectively Disrupts Redox Balance in Hepatoma Cells and Reduces Growth of Orthotopic Liver	46 8 4
84 83 82 81	The rationale for targeting TGF-IIn chronic liver diseases. 2016, 46, 349-61  Limitations of the barcelona clinic liver cancer staging system with a focus on transarterial chemoembolization as a key modality for treatment of hepatocellular carcinoma. 2016, 7, 32-35  Erratum to: Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis. 2016, 36, 93-6  Hepatic Arterial Infusion of Low-Density Lipoprotein Docosahexaenoic Acid Nanoparticles Selectively Disrupts Redox Balance in Hepatoma Cells and Reduces Growth of Orthotopic Liver Tumors in Rats. 2016, 150, 488-98  Investigation of long noncoding RNAs expression profile as potential serum biomarkers in patients	46 8 4 34
84 83 82 81 80	The rationale for targeting TGF-IIn chronic liver diseases. 2016, 46, 349-61  Limitations of the barcelona clinic liver cancer staging system with a focus on transarterial chemoembolization as a key modality for treatment of hepatocellular carcinoma. 2016, 7, 32-35  Erratum to: Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis. 2016, 36, 93-6  Hepatic Arterial Infusion of Low-Density Lipoprotein Docosahexaenoic Acid Nanoparticles Selectively Disrupts Redox Balance in Hepatoma Cells and Reduces Growth of Orthotopic Liver Tumors in Rats. 2016, 150, 488-98  Investigation of long noncoding RNAs expression profile as potential serum biomarkers in patients with hepatocellular carcinoma. 2016, 168, 134-145  Prediction of development of hepatocellular carcinoma using a new scoring system involving	46 8 4 34 77

76	Value of tumor stiffness measured with MR elastography for assessment of response of hepatocellular carcinoma to locoregional therapy. <b>2017</b> , 42, 1685-1694		25
75	Quantitative analysis of gadoxetic acid-enhanced magnetic resonance imaging predicts histological grade of hepatocellular carcinoma. <b>2017</b> , 43, 9-14		9
74	Pesticide exposure and liver cancer: a review. Cancer Causes and Control, 2017, 28, 177-190	2.8	49
73	The Liver: General Aspects and Epidemiology. <b>2017</b> , 3-22		13
72	Geographic epidemiology of hepatocellular carcinoma, viral hepatitis, and socioeconomic position in New York City. <i>Cancer Causes and Control</i> , <b>2017</b> , 28, 779-789	2.8	9
71	Long non-coding RNA AB019562 promotes cell proliferation and metastasis in human hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , <b>2017</b> , 16, 69-74	2.9	6
70	Diagnostic accuracy of osteopontin plus alpha-fetoprotein in the hepatocellular carcinoma: A meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2017</b> , 41, 543-553	2.4	7
69	Non-invasive quantitative imaging of hepatocellular carcinoma growth in mice by micro-CT using liver-targeted iodinated nano-emulsions. <i>Scientific Reports</i> , <b>2017</b> , 7, 13935	4.9	18
68	Serum fibronectin distinguishes the early stages of hepatocellular carcinoma. <i>Scientific Reports</i> , <b>2017</b> , 7, 9449	4.9	30
67	Anticancer mechanisms of Blume hexane extract on liver and breast cancer cell lines. <i>Oncology Letters</i> , <b>2017</b> , 14, 4957-4964	2.6	9
66	Trends and outcomes of transarterial chemoembolization in hepatocellular carcinoma: a national survey. <i>Hepatobiliary and Pancreatic Diseases International</i> , <b>2017</b> , 16, 624-630	2.1	4
65	Tumors of the liver. <b>2017</b> , 1272-1298.e7		
64	From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world. <i>World Journal of Gastroenterology</i> , <b>2017</b> , 23, 5282-5294	5.6	158
63	S-1 for treatment of advanced hepatocellular carcinoma: a systematic review of the literature. <i>Wspolczesna Onkologia</i> , <b>2017</b> , 21, 16-20	1	О
62	Contrast-Enhanced Ultrasonography Versus Contrast-Enhanced Computed Tomography for Assessment of Residual Tumor From Hepatocellular Carcinoma Treated With Transarterial Chemoembolization: A Meta-analysis. <i>Journal of Ultrasound in Medicine</i> , <b>2018</b> , 37, 1881-1890	2.9	7
61	Liver transplantation for hepatocellular carcinoma within the Milan criteria versus the University of California San Francisco criteria: a comparative study. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2018</b> , 30, 398-403	2.2	7
60	Hospice care in Medicare patients with primary liver cancer: the impact on resource utilisation and mortality. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 680-688	6.1	9
59	Phenformin-Induced Mitochondrial Dysfunction Sensitizes Hepatocellular Carcinoma for Dual Inhibition of mTOR. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 3767-3780	12.9	13

58	Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma. <i>Molecular and Cellular Biochemistry</i> , <b>2018</b> , 437, 13-36	4.2	27
57	Optimizing hepatectomy for hepatocellular carcinoma in Asia-patient selection and special considerations. <i>Translational Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 75	5.2	6
56	Angiotensin II: a key mediator in the development of liver fibrosis and cancer. <i>Bulletin of the National Research Centre</i> , <b>2018</b> , 42,	3	18
55	Liver and Pancreas. <i>Molecular Pathology Library</i> , <b>2018</b> , 281-329		
54	Biomarkers of Exposure, Effect, and Susceptibility. <b>2018</b> , 188-201		
53	Barriers to Care in Chinese Immigrants with Hepatocellular Carcinoma: A Focus Group Study in New York City. <i>Journal of Community Health</i> , <b>2018</b> , 43, 1161-1171	4	4
52	Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , <b>2019</b> , 10, 554-561	2.8	16
51	Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , <b>2019</b> , 20, 3773-3781	2.9	23
50	Risk of Hepatocellular Carcinoma Following Use of Direct Acting Antiviral Medications for Treatment of Chronic Hepatitis C. <i>Cancer Prevention Research</i> , <b>2019</b> , 12, 891-902	3.2	1
49	Hepatocellular Carcinoma and Associated Clinical Features in Latino and Caucasian Patients from a Single Center. <i>Annals of Hepatology</i> , <b>2019</b> , 18, 177-186	3.1	5
48	Enrichment in selected genotypes, basal core and precore mutations of hepatitis B virus in patients with hepatocellular carcinoma in Cameroon. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 1086-1093	3.4	8
47	Environmental health in the biology century: Transitions from population to personalized prevention. <i>Experimental Biology and Medicine</i> , <b>2019</b> , 244, 728-733	3.7	2
46	Biliary Tract and Primary Liver Tumors: Who, What, and Why?. Surgical Oncology Clinics of North America, <b>2019</b> , 28, 519-538	2.7	3
45	Imaging-Negative Hepatocellular Carcinoma Presents as an Intrabiliary Mass. <i>ACG Case Reports Journal</i> , <b>2019</b> , 6, e00068	0.6	1
44	The Long-To-Short-Axis Ratio and Multifocality are Associated With TP53 Mutation Status in Surgically Resected Hepatocellular Carcinomas. <i>Academic Radiology</i> , <b>2020</b> , 27, 1720-1726	4.3	2
43	The Burden and Trends of Primary Liver Cancer Caused by Specific Etiologies from 1990 to 2017 at the Global, Regional, National, Age, and Sex Level Results from the Global Burden of Disease Study 2017. <i>Liver Cancer</i> , <b>2020</b> , 9, 563-582	9.1	37
42	S100A4 promotes hepatocellular carcinogenesis by intensifying fibrosis-associated cancer cell stemness. <i>Oncolmmunology</i> , <b>2020</b> , 9, 1725355	7.2	8
41	Changing Etiology and Epidemiology of Human Liver Cancer. <b>2021</b> , 13-29		

40	Factors predicting staging and treatment initiation for patients with chronic hepatitis C infection: insurance a key predictor. <i>Journal of Public Health</i> , <b>2021</b> ,	3.5	О
39	Alkaloidal Extract Improves CCl-Induced Hepatocellular Carcinoma-Like Phenotypes in Rats. <i>Evidence-based Complementary and Alternative Medicine</i> , <b>2021</b> , 2021, 3804379	2.3	3
38	Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2021</b> , 45, 101713	2.4	3
37	Yttrium-90 Radioembolotherapy for Hepatocellular Cancer. <b>2011</b> , 319-335		4
36	The Liver. <b>2012</b> , 1411-1475		5
35	Hepatocellular Carcinoma in Oman: An analysis of 284 cases. <i>Sultan Qaboos University Medical Journal</i> , <b>2020</b> , 20, e316-e322	0.9	3
34	The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma. <i>Oncotarget</i> , <b>2017</b> , 8, 15846-15	5857	32
33	Contrast-enhanced computed tomography plus gadolinium-ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging for gross classification of hepatocellular carcinoma. <i>Oncotarget</i> , <b>2017</b> , 8, 29741-29750	3.3	2
32	Epigenetic signatures of alcohol abuse and hepatitis infection during human hepatocarcinogenesis. <i>Oncotarget</i> , <b>2014</b> , 5, 9425-43	3.3	61
31	Liver Cancer Mortality and Food Consumption in Serbia, 1991-2010: An Ecological Study. <i>Central European Journal of Public Health</i> , <b>2016</b> , 24, 103-8	1.2	1
30	Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients. <i>World Journal of Gastroenterology</i> , <b>2011</b> , 17, 914-21	5.6	15
29	Hepatitis C virus induced insulin resistance impairs response to anti viral therapy. <i>World Journal of Gastroenterology</i> , <b>2012</b> , 18, 212-24	5.6	41
28	Hepatocellular Carcinoma: Risk Factors, Diagnosis, Staging and Treatment in a Referral Centre. Journal of Cancer Therapy, <b>2013</b> , 04, 384-393	0.2	2
27	Molecular Targeted Therapy of Hepatocellular Carcinoma. <i>Journal of Cancer Therapy</i> , <b>2013</b> , 04, 426-439	0.2	7
26	Serum SCCA-IgM as a predictor of hepatocellular carcinoma in patients with liver cirrhosis. <i>Open Journal of Gastroenterology</i> , <b>2012</b> , 02, 56-61	0.2	14
25	Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. <i>World Journal of Hepatology</i> , <b>2015</b> , 7, 2274-91	3.4	39
24	Liver Cancer in Enugu, South East Nigeria. <b>2011</b> , 1, 1-5		7
23	Association of Hepatitis C Virus With Insulin Resistance: Evidences From Animal Studies and Clinical Studie. <i>Hepatitis Monthly</i> , <b>2012</b> , 12, 11-15	1.8	2

22 Environmental Carcinogens and Risk for Human Liver Cancer. 2009, 27-53

21	Melanoma and Primary Hepatocellular Carcinoma. <b>2009</b> , 227-256		1
20	Evaluation of Focal Liver Masses. <b>2010</b> , 173-179		
19	Intraoperative Evaluation of Primary Hepatocellular Tumors. Frozen Section Library Series, 2011, 1-20		
18	Hepatitis Viruses: Hepatitis C. <b>2014</b> , 765-783		
17	The Impact of Treating Chronic Liver Diseases on Hepatocellular Carcinoma Prevention. <b>2012</b> , 229-246		
16	HCC RADIOLOGINB DIAGNOSTIKOS KITIMAS LIETUVOS SVEIKATOS MOKSLŪNIVERSITETO KAUNO KLINIKOSE 20030014 METAIS. <i>Medicinos Teorija Ir Praktika</i> , <b>2015</b> , 21, 553-558		
15	Metabolic Syndrome and the Liver. <b>2016</b> , 149-177		
14	Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. 2017, 83-91		
13	Living donor liver transplantation in hepatocellular carcinoma: A single-center experiences. <i>Journal of Surgery and Medicine</i> ,	0.1	O
12	Association of Hepatitis C Virus With Insulin Resistance: Evidences From Animal Studies and Clinical Studie. <i>Hepatitis Monthly</i> , <b>2012</b> , 12, 11-15	1.8	
11	A multidisciplinary approach to the management of hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , <b>2010</b> , 6, 1-16	0.7	7
10	Transarterial chemoembolization with Doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma. <i>Gastrointestinal Cancer Research: GCR</i> , <b>2011</b> , 4, 2-8		10
9	Association of hepatitis C virus with insulin resistance: evidences from animal studies and clinical studies. <i>Hepatitis Monthly</i> , <b>2012</b> , 12, 11-5	1.8	3
8	Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , <b>2010</b> , 6, 1-16	0.7	
7	Liver Transplantation for Hepatocellular Carcinoma among African Americans in the United States. <i>International Journal of Organ Transplantation Medicine</i> , <b>2012</b> , 3, 85-91	0.7	O
6	Effects of statins on the risk of hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , <b>2014</b> , 10, 417-26	0.7	15
5	Achieving health equity to eliminate racial, ethnic, and socioeconomic disparities in HBV- and HCV-associated liver disease. <i>Journal of Family Practice</i> , <b>2010</b> , 59, S37-42	0.2	10

## CITATION REPORT

4	The Applicability of a Human Immunohistochemical Panel to Mouse Models of Hepatocellular Neoplasia. <i>Comparative Medicine</i> , <b>2015</b> , 65, 398-408	1.6	7
3	Impact of circ-0000221 in the Pathogenesis of Hepatocellular via Modulation of miR-661-PTPN11 mRNA Axis <i>Pharmaceutics</i> , <b>2022</b> , 14,	6.4	
2	Frailty as a Predictor of Complications and Transplant-Free Survival after Transarterial Chemoembolization of Hepatocellular Carcinoma. <i>Journal of Clinical Interventional Radiology ISVIR</i> ,	0.5	
1	Association between trends of mortality and incidence, survival and stage at diagnosis for six digestive and respiratory cancers in United States (2009\( \textbf{D} 013 \)). Publish Ahead of Print,		